Q4 2024 Avicanna Inc Earnings Call Transcript
Key Points
- Avicanna Inc (AVCNF) reported record revenues of $25.5 million in 2024, marking a 52% growth from the previous year.
- The company's gross profit increased by 94% to $12.9 million, with gross margins rising to 51%, attributed to optimization efforts and increased licensing and service revenue.
- Avicanna Inc (AVCNF) achieved significant advancements in its pharmaceutical pipeline, including the first pharmaceutical approval with Trunerox in Colombia.
- The MyMedi platform generated $21.7 million in gross revenue, reflecting strong adoption and a central role in Avicanna's Canadian commercial strategy.
- The company has successfully expanded its international operations, completing transactions in 22 international markets and advancing its proprietary products like Trunerox and cosmetic topicals.
- Despite improvements, Avicanna Inc (AVCNF) reported an adjusted EBITDA loss of $1.4 million in 2024.
- Operating expenses increased by 17% over 2023, primarily due to the first full year of operating the MyMedi platform.
- The company faced a delay in its 2024 filings due to an internal jurisdictional licensing matter with its auditors.
- Avicanna Inc (AVCNF) continues to operate with a working capital deficit, although it has decreased from $3.9 million to $1.6 million.
- The launch of Trunerox in Central and South America is expected to take longer due to regulatory challenges, with a soft launch planned for early Q3 in Colombia.
So good morning, everyone. Thank you for joining our 2024 earnings and corporate update. I'm joined here with Phil Cardella, who's our CFO. And together, we'll be providing an overview of our 2024 results, a brief look into the future. And at the end of the presentation, we'll leave some time to take direct questions from the audience as well.
I'll now hand it over to Phil to provide a brief administrative note.
Thanks, Aras. Before we begin, just a quick disclaimer. We may refer to forward-looking statements that are subject to risks and uncertainties that may differ from the actual results. We list risks, uncertainties and other factors that may cause our results to differ materially on slide 2. These statements are based upon current information, beliefs and assumptions, and we disclaim any obligation to update them, except where required by law. Although we believe the current information, beliefs and assumptions underlying these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
